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Molecular genetic case-control women investigation 
from the first Brazilian high-risk study on 
functional psychosis
Investigação genético-molecular do tipo 
caso-controle em uma amostra de mulheres 
portadoras de psicose funcional do primeiro 
estudo de alto-risco brasileiro
Abstract
Objective: Data from epidemiological studies have demonstrated that genetics is an important risk factor for psychosis. The present study 
is part of a larger project, pioneer in Brazil, which has been conducted by other researchers who intend to follow a high-risk population 
(children) for the development of schizophrenia and bipolar disorder. In this first phase of the project, the objective was to investigate 
the distribution of four candidate genetic polymorphisms for functional psychosis (Ser9Gly DRD3, 5HTTLPR, the VNTR 3’-UTR SLC6A3 
and Val66Met BDNF) in a case-control sample. Method: A total of 105 women (58 with schizophrenia and 47 with bipolar disorder) 
and 62 gender-matched controls were investigated. Results: Allele and genotype distributions of all identified functional polymorphisms 
did not differ statistically between cases and controls. Conclusions: These results suggest that the investigated polymorphisms were not 
related to susceptibility to functional psychoses in our Brazilian sample. These findings need to be validated in larger and independent 
studies.
Descriptors: Schizophrenia; Bipolar disorder; DAT1 gene; SLC6A3 gene; DRD3 gene; Brain-derived neurotrophic factor gene
Resumo
Objetivo: Estudos epidemiológicos demonstram que alterações genéticas são fatores de risco importantes para o desenvolvimento de 
psicose. O presente estudo é parte um projeto maior, pioneiro no Brasil, realizado com mais pesquisadores, que pretende seguir uma 
população de alto risco genético para o desenvolvimento de esquizofrenia e transtorno bipolar. Nesta primeira fase, o objetivo foi inves-
tigar a distribuição de quatro polimorfismos genéticos candidatos no desenvolvimento de psicose funcional (Ser9Gly DRD3, 5HTTLPR, 
o VNTR 3’-UTR SLC6A3 e Val66Met BDNF) em uma amostra caso-controle. Método: Um total de 105 mulheres (58 esquizofrenia e 
47 transtorno bipolar) e 62 controles sem diagnóstico psiquiátrico foi investigado. Resultados: Nenhuma diferença estatisticamente 
significante foi observada nas distribuições alélicas e genotípicas entre os grupos investigados. Conclusões: Os resultados sugerem 
que estes polimorfismos não estavam relacionados à suscetibilidade para psicose funcional nesta amostra brasileira estudada. Esses 
achados precisam ser validados em estudos maiores e independentes.
Descritores: Esquizofrenia; Transtorno bipolar; Gene DAT1; Gene SLC6A3; Gene DRD3; Gene do fator neurotrófico derivado do 
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Introduction
The diagnostic difference between schizophrenia and bipolar 
disorder has been for more than a century based on differences in 
phenomenology and outcome.1 However, the distinction or even the 
real existence of both diagnostic categories has been progressively 
challenged. The accumulated evidence against it has come from 
a great number of studies such as follow-up, family, twin and 
neurobiological investigations for both disorders.2
Interestingly, both schizophrenia and bipolar disorders present 
a good number of studies demonstrating the existence of an 
important genetic factor for their development. The contribution 
of the genetic component for the susceptibility of schizophrenia or 
bipolar disorder is about 70% of the total variance for each disorder. 
Many molecular genetic studies have been carried out, and their 
results have indicated some common specific chromosomal areas 
or DNA markers for both phenotypes, suggesting a further support 
for revising the concept of these diagnostic categories.3
An alternative to validate a better phenotype for the investigation 
of putative genes for schizophrenia and bipolar disorder is the 
use of a broader concept called functional psychosis. However, 
this term contains not only the categories of schizophrenia and 
bipolar disorder, but also schizoaffective disorder and psychotic 
depression.4
It has been suggested that if a better phenotype (i.e. closer to the 
true clinical characterization associated with the underlying “disease 
genes”) is used, the molecular genetic studies will identify these 
genes with certainty.2
One of the most common strategies in molecular genetics to 
identify genes associated with complex disorders has been the 
utilization of the association study design. This method investigates 
genes (usually selected a priori as a viable choice based on previous 
scientific results – they are also called “candidate genes”) with small 
to moderate effect for the development of the phenotypes.5
The present research team is pioneer in Brazil and will follow 
children with a high genetic/biological risk for functional psychosis 
(their mothers have bipolar disorder or schizophrenia) and will 
compare them with children without such risk.6 Although these 
children present high genetic/biological risk for the development 
of psychotic disorders, they do not present such disorders at the 
moment. Therefore, the aim of the present study was to investigate 
the role of polymorphisms from candidate genes for the development 
of psychosis in the mother sample, in a case-control approach, in 
order to replicate its results in future investigations with the sample 
of children.
The polymorphisms were investigated in four important genes, 
dopamine receptor subtype 3 gene (DRD3), the brain-derived 
neurotrophic factor gene (BDNF) and the serotonin and dopamine 
transporters genes (5HTT and DAT1/SLC6A3, respectively) 
in the mothers and compare them with a non-psychotic 
gender-matched group.
One representative functional polymorphism from each gene was 
chosen, the serine-to-glycine amino acid substitution at position 
9 (Ser9Gly) in the N-terminal domain of the DRD3 (rs6280); a 
functional 44-bp insertion/deletion polymorphism (5HTTLPR) in 
the promoter region of the 5HTT; a variable number of tandem 
repeats (VNTR) polymorphism in the 3’-untranslated region of the 
SLC6A3; a non-conservative substitution from valine to methionine 
at amino acid position 66 (Val66Met) in the pro-domain of BDNF 
(rs6265).
These genes have been usually investigated in studies on 
schizophrenia and bipolar disorder as separated phenotypes. 
However, studies with the dimensional or continuum approach in 
functional psychosis phenotype have been uncommon.  
A meta-analysis with the Ser9Gly DRD3 polymorphism 
accomplished by Jönsson et al.7 has found a relative risk of 
homozygosis (Ser/Ser and Gly/Gly), with odds ratio varying from 
1.08 to 1.10 for the development of schizophrenia. On the other 
hand, association studies on bipolar disorder and the Ser9Gly DRD3 
polymorphism have not found positive results.8
The studies with 5HTT have found inconsistent findings 
regarding the association between the 5HTTLPR polymorphism and 
functional disorder. However, Cho et al.9 have found a significant 
pooled odds ratios of 1.12 for 5-HTTLPR as risk factor for bipolar 
disorder. 5HTTLPR has been considered functionally biallelic, even 
though other genetic variations were known. 5HTTLPR consists of 
varying numbers of copies of a 20–23-basis-pairs imperfect repeat 
sequence. Substantial interpopulation variation occurs. Rare alleles 
contain up to 20 copies of the repeat.9 On the other hand, none of 
these additional alleles was found to be functional. Therefore, it has 
been possible to use different methods in the genotype exploratory 
data analysis in the study of this polymorphism. However, recently 
a third functional allele of this genetic variant was discovered, 
which is an A > G single nucleotide polymorphism within the first 
of two extra repeats that characterize the “insertion” allele.10 As 
such discovery occurred after the beginning of the present work, 
unfortunately the genetic analysis of this paper did not take into 
account the existence of this new allele.
Although some studies have found positive association between 
the VNTR 9/9 and 10/10 polymorphisms of DAT1 and risk 
for schizophrenia,11,12 most of them have not supported these 
findings.13 Other studies have found positive association with 
negative symptoms,14 loss of dopaminergic neurons and/or decrease 
in the expression of DAT1 in patients with chronic schizophrenia.15
Finally, in a meta-analysis with 659 schizophrenic and 563 controls, 
even though there was over 90% of power to detect a significant 
odds ratio as small as 1.3, no association was observed.16
In a recent meta-analysis, there was no evidence of association 
of the Val66Met polymorphism of BDNF and increased risk for 
schizophrenia (2,955 patients and 4,035 controls) or bipolar 
disorder (3,143 patients and 6,347 controls), with pooled odds 
ratios of 1.00 (p = 0.944) and 0.95 (p = 0.161).17 Xu et al.,18 in
their population-based study and meta-analysis, have demonstrated 
that the Val66Met BDNF polymorphism should not play major roles 
in the susceptibility for schizophrenia in either Caucasian or Asian 
populations.
Method
The present study was approved by the Ethics Committee of the 
Universidade de São Paulo Medical School (process: 030/05). After 
explanations on the research and approval by the participants, all 
of them provided written informed consent. This is a cross-sectional 
study and part of a larger investigation with mothers and children 
with high genetic/biological risk for schizophrenia and bipolar 
disorder. In the present study allele and genotype frequencies 
from the investigated polymorphisms were compared between the 
groups of women with schizophrenia and bipolar disorder with 
children between 6 and 18 years old (case sample), originating 
from the Institute of Psychiatry of the Hospital das Clínicas of the 
Universidade de São Paulo Medical School, and women without 
such psychiatric disorders (control sample) from the Gynecologic 
Clinic of the same university with same-age children. Individuals 
unable to answer the questionnaire of evaluation, to understand the 
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term of informed consent, and to refuse the donation of blood for 
genetic analysis were excluded from the study. For the participants 
in the investigation, blinded interviews were administered using the 
Structured Clinical Interview for Diagnostic and Statistical Manual 
of Mental Disorders (SCID-I) and a sample of blood was collected 
for genetic analysis.19
The deoxyribonucleic acid (DNA) extraction was performed 
using the “salting out” method described by Miller et al.20 and the 
amplification of all polymorphisms studied was performed using 
polymerase chain reaction (PCR). A different PCR condition was 
used for each polymorphism: VNTR SLC6A3 by Vandenbergh et
al.;21 DRD3 Ser9Gly by Lannfelt et al.;22 5HTTLPR by Heils et al.;23
BDNF Val66Met by Rozen & Skaletsky.24
The groups were compared using Pearson’s chi-square test or 
Fisher’s exact test for categorical variables using the Statistical 
Program for Social Sciences (SPSS). The polymorphism frequency 
differences were investigated with Pearson’s chi-square test using the 
Clump v1.9. The significance value adopted was 0.05. The Hardy-
Weinberg equilibrium was tested using the HWE Program.25
Results
The total number of individuals investigated was 105 women 
with functional psychosis (58 with schizophrenia and 47 with 
bipolar disorder). These patients were compared with 62 women 
(mothers) without functional psychosis. The mean age was 40.27 
(SD ± 6.32) (no statistical difference between the groups).
The power of the sample, based on 105 patients and 62 
controls, disorder prevalence rate of 3% in the general population 
(schizophrenia and bipolar disorder), allelic frequency close to 
30%, multiplicative model with the genotype relative risk = 1.7, 
and significance level of 0.05, was lower than 70%. Despite that, 
underpowered non-significant study of possible real associations 
with modest genetic effects can reasonably account for much of 
the variability in replication and can contribute for meta-analysis (in 
cases of modest genetic effects that would be hard to replicate in 
small studies, meta-analysis may be interesting because it avoids 
type I errors, false positive).
There were no significant deviations from the Hardy-Weinberg 
equilibrium in any of the samples for the polymorphisms studied. 
Case-control analysis provided no differences in genotypic 
distributions, as well as homozygosis between psychosis and 
control samples (Table 1). Considering that the homogeneity of the 
genotypic proportions between the groups of patients and controls 
was not rejected (H: p1 = q1, p2 = q2 e p3 = q3), and for this 
reason any function of these proportions could be rejected as well 
(H’: P1 + (1/2)p2 = q2 + (1/2)q2), it was not necessary to conduct 
the allelic analysis (a function of the genotypic proportions).
The DAT1 polymorphism presents many rare alleles (e.g.: 8 and 
11). This increases the degrees of freedom of the test and reduces 
the power of the sample. However, no statistical difference was 
observed even when the analysis was performed again (Table 2).
Discussion
The present research investigated the allelic and genotypic 
distributions of polymorphisms from four candidate genes in 167 
women (105 with psychosis and 62 controls) with the aim of 
studying their role as genetic susceptibility for functional psychosis. 
The results have not given support for the association of such 
polymorphisms as risk factors for the investigated phenotype.
The ethnic admixture of the Brazilian sample may be a bias in 
genetic association studies. To face such a problem, identification 
of the ethnic origin of the sample and homogenous samples may 
be of great help. However, in Brazil physical characteristics such as 
skin pigmentation, hair color and texture, shape of the nose and lips, 
are poor predictors of genomic ancestry,26 which makes it difficult 
to achieve ethnic matching in case-control studies. Nevertheless, 
the fact that the present sample is in Hardy-Weinberg equilibrium 
indicates that the sample may not have important problems of 
population stratification.27 Moreover, ethnic matching conducted 
using genetic markers was performed in part of our sample in a 
case-control study with cocaine dependence and the results showed 
that despite the ethnic admixture in Brazil the ethnic stratification 
was not a bias in that case.28 In spite of that, we are aware that 
ethnic admixture may be a limitation for the present work.
The fact that a third recently discovered functional allele of the 
5HTTLPR polymorphism has not been analyzed in the present 
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include the offspring of the patients from the main study to replicate 
the present findings, introduce larger number of participants and 
analyze the offspring (clinic and genetics) using the microarray 
technique.
The technique known as microarray is particularly powerful in 
providing a global view of gene expression patterns in biological 
samples. By the simultaneous determination of the expression levels 
of thousands of genes, microarrays allow researchers to compare 
the molecular behavior of different types of cells that have been 
exposed to pathological or experimental conditions.29
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study, as mentioned before, may be related to the lack of association 
between such polymorphism and the investigated disorders. Another 
possible methodological limitation of the present study may be the 
sample size.
In a follow-up study it is possible to change the experimental 
drawing and the investigation techniques. Our group will also 
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